Agenus to Provide Corporate Update and Third Quarter 2022 Financial Report
Agenus (NASDAQ: AGEN) announced it will release its Q2 2022 financial results before the market opens on November 8, 2022. The company will host a conference call at 8:30 a.m. ET to discuss the results and provide updates. On November 12, 2022, Agenus will hold an R&D event titled “The Road Taken” in Boston, featuring insights from oncology experts regarding botensilimab and its development in cold tumors. Investors may access the conference call and R&D event via dial-in and webcast, respectively.
- Hosting a significant R&D event to discuss botensilimab development in cold tumors.
- Engaging with leading cancer immunologists to share expertise and insights.
- None.
- Conference Call on Tuesday, November 8, 2022, at 8:30 a.m. ET
- Company to host “The Road Taken” R&D Event in Boston on November 12 from 2p.m. – 5p.m. ET to discuss with oncology experts clinical experience to date and expected development plans for botensilimab in cold tumors
LEXINGTON, Mass., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN) an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced the Company will release its second quarter 2022 financial results before the market opens on Tuesday, November 8, 2022. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and to provide a corporate update.
Conference Call
Dial-in numbers: (646) 307-1963 (US-NY) or (800) 715-9871 (US & CA)
Event ID: 6199615
Webcast
A webcast and replay of the conference call will be accessible from the Events & Presentations page of the Company’s website at https://investor.agenusbio.com/events-and-presentations and via https://edge.media-server.com/mmc/p/xh3u6boi.
“The Road Taken” R&D Event
Agenus will host an in-person and virtual R&D event (“The Road Taken”) on Saturday, November 12th, 2022, from 2:00 p.m. to 5:00 p.m. ET at the Prudential Tower in Boston, MA. The event will feature insights from leading cancer immunologists who will share their collective and individual expertise on the current and future state of cancer immunotherapy, including a deep dive into the botensilimab data presented at SITC. Institutional investors, research analysts, and key opinion leaders are invited to attend the Event in-person and can RSVP by emailing investorrelations@agenusbio.com. To register for the live webcast, please click here.
About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer and infections. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its subsidiary MiNK Therapeutics), and adjuvants (through its subsidiary SaponiQx). The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter.
Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements relating to our technologies, therapeutic candidates, and capabilities, for instance, statements regarding therapeutic benefit and efficacy, mechanism of action, potency, durability, and safety and tolerability profile of our therapeutic candidates, both alone and in combination with each other and/or other agents; statements regarding future plans, including research, clinical, regulatory, and commercialization plans; and any other statements containing the words "may," "believes," "expects," "anticipates," "hopes," "intends," "plans," "will" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission and available on our website: www.agenusbio.com. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
Contact
Agenus Inc.
Nico Frelick
Investor Relations
781-674-4616
nico.frelick@agenusbio.com
FAQ
When will Agenus release its Q2 2022 financial results?
What is the conference call about for Agenus on November 8, 2022?
What is the focus of the R&D event hosted by Agenus on November 12, 2022?
How can I access Agenus's conference call and R&D event?
